Biocon gains after Health Canada nod for cancer, osteoporosis drugs
Biocon's subsidiary, Biocon Biologics, received Health Canada approval for its biosimilars Yesintek and Yesintek I.V., which are biosimilars of ustekinumab. This approval, granted on October 17, 2025, allows for their commercial launch in Canada by mid-October 2025, strengthening the company's presence in the North American immunology market, valued at over CAD 1 billion annually.
Apr 21 2026 10:04:00
Biocon Limited
Biocon received Health Canada approval on April 3, 2026, for its biosimilars Bosaya (denosumab) and Vevzuo (denosumab). This expands access to high-quality biologic therapies for osteoporosis and cancer-related bone conditions in key global markets.
Apr 21 2026 08:04:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon receives Health Canada approval for its denosumab biosimilars, Bosaya™ and Vevzuo™, on April 3, 2026. These biosimilars are indicated for osteoporosis and various cancer-related bone conditions.
Apr 21 2026 08:04:00
Biocon Limited
Biocon Limited has issued a reminder to shareholders holding physical shares to update their KYC details. This is crucial for shareholders to continue receiving payments such as dividends and interest, aligning with SEBI Master Circular dated February 06, 2026.
Apr 20 2026 20:04:00
Biocon Limited
Biocon Pharma Ltd received U.S. FDA approval for Dapagliflozin Tablets (5 mg and 10 mg). This approval strengthens the company's diabetes portfolio, with manufacturing to occur at its FDA-approved facilities.
Apr 08 2026 08:04:00
Biocon Limited
Biocon management will participate in the HSBC Global Investment Summit 2026 and an Investor Roadshow from April 14-17, 2026. These meetings will take place in Hong Kong and Singapore to engage with analysts and investors.
Apr 07 2026 20:04:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Biocon management will participate in the HSBC Global Investment Summit in Hong Kong and an Investor Roadshow in Singapore from April 14-17, 2026. These meetings are with analysts and institutional investors; no unpublished price sensitive information will be disclosed.
Apr 07 2026 20:04:00
Biocon Limited
Biocon announced the U.S. commercial launch of its denosumab biosimilars, Bosaya and Aukelso, for osteoporosis and cancer-related bone conditions. These products received interchangeable designation from the U.S. FDA in September 2025, enabling broader access to high-quality treatment options for patients.
Apr 07 2026 16:04:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon announced the U.S. commercial launch of its denosumab biosimilars, Bosaya™ and Aukelso™. These products are now available nationwide after receiving interchangeable designation from the U.S. FDA in September 2025.
Apr 07 2026 16:04:00
Biocon Ltd - 532523 - Amendment To Trust Deed
Biocon Limited amended its Employees Welfare Trust Deed, changing the composition of its Trustees. Two existing Trustees resigned, and two new Trustees were appointed, effective April 1, 2026, to manage the Employee Welfare Trust.
Mar 27 2026 12:03:00
Read More